Comment on “is Phaeohyphomycosis an emerging fungal Infection in Iran? A Short Communication

Abstract

Dear editor We recently read an interesting article entitled “Is Phaeohyphomycosis an emerging fungal Infection in Iran? A Short Communication” [1] which is published in your journal. This article discusses the prevalence of Phaeohyphomycosis cases in Iran. We published an article entitled “Cerebral Phaeohyphomycosis due to Rhinocladiella mackenziei in Persian Gulf region: A case and review” in 2018 [2]. Our case was a diabetic patient with the history of behcet's disease and with the diagnosis of brain abscesses due to Rhinocladiella mackenziei. For the patient we prescribed voriconazole at first then change the regimen to amphotericin b liposomal (5 mg/kg/day) with combination of posaconazole (200 mg every 6 hours). In the article published by zarrinfar et al recently [1], the authors have referenced our article [2] and instead of the original dose for posaconazole (200 mg every 6 hours), which we also had stated the dose in our article (200 mg every 6 hours), the authors have written wrong dose (200 mg daily) in the table. The dose of posaconazole for treatment is 200 mg every 6 hours and for prophylaxis is 200 mg every 8 hours. We request that this wrong dose be corrected in the table of article published in your journal.